AbbVie Stock News

Dividend stocks are a foundational building block for creating a retirement portfolio, offering a reliable income stream and potential for capital appreciation.

Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.

Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.

AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This protein is known to promote tumor growth and resistance to certain therapies.

NEW YORK , May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors that are less ambiguous. ABBV's superior dividend track record, safer payout ratio, consistent share buybacks, and robust margins make it an overall better package compared to PFE.

AbbVie Inc. (NYSE:ABBV ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ET Company Participants Jeff Stewart - EVP and Chief Commercialization Officer Roopal Thakkar - EVP and R&D, Chief Scientific Officer Scott Reents - EVP and CFO Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this next session. I'm Tim Anderson, the U.S. la...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.